Business Context and Reporting Period
PowerVerde, Inc. (identified in the request metadata as 374Water Inc.) filed this unaudited Form 10-Q for the quarter ended March 31, 2013. The filing identifies the registrant as PowerVerde, Inc., a development-stage company focused on developing and commercializing clean-energy electric power systems. Planned principal operations had not commenced, and the company continued to rely on licensing revenue and debt and equity financing.
The company reported 26,400,106 common shares outstanding as of May 20, 2013. It was classified as a smaller reporting company and stated that it was not a shell company.
Key Financial Metrics
| Metric | Three months ended March 31, 2013 | Comparable 2012 period |
|---|---|---|
| Revenue | $71,487 | $14,435 |
| Cost of goods sold | $0 | $0 |
| Gross profit | $71,487 | $14,435 |
| Research and development expense | $236,157 | $577,036 |
| General and administrative expense | $452,677 | $221,239 |
| Total operating expenses | $688,834 | $798,275 |
| Loss from operations | $(617,347) | $(783,840) |
| Net loss | $(596,335) | $(787,484) |
| Basic and diluted loss per share | $(0.02) | $(0.03) |
Revenue consisted of biotech intellectual-property licensing fees; the company reported no product-sales revenue in either period. Gross margin was 100% in both periods based on reported revenue and zero cost of goods sold. The company had a cumulative development-stage deficit of $10.2 million through March 31, 2013.
| Balance-sheet metric | March 31, 2013 | December 31, 2012 |
|---|---|---|
| Cash and cash equivalents | $12,732 | $45,283 |
| Total current assets | $120,680 | $207,611 |
| Total assets | $568,572 | $711,750 |
| Total current liabilities | $264,557 | $280,332 |
| Total liabilities | $543,929 | $532,949 |
| Stockholders’ equity | $24,643 | $178,801 |
| Derivative liability | $44,000 | $68,250 |
Working-capital deficit was $143,877 at March 31, 2013, compared with $72,721 at December 31, 2012. Related-party payables totaled $363,370, including $127,998 current and $235,372 long term.
Operating activities used $107,551 of cash, compared with $236,355 in the prior-year quarter. Financing activities provided $75,000 from related-party secured promissory notes. Net cash decreased by $32,551 during the quarter. No cash was used for investing activities.
Material Changes Versus the Prior Comparable Period
- Revenue increased $57,052, or approximately 395%, to $71,487, entirely from licensing fees rather than product sales.
- Research and development expense declined $340,879, or 59.1%, because the company was testing systems and was not building new generator systems.
- General and administrative expense increased $231,438, or 104.6%, primarily because of employee and consultant compensation, including stock-based compensation.
- Net loss improved by $191,149, or 24.3%, but the company remained unprofitable.
- Cash declined by $32,551, while the working-capital deficit widened by approximately $71,156.
- The company raised $75,000 through secured promissory notes issued to existing stockholders. The notes bear 10% annual interest and mature December 31, 2014.
- The company issued 325,000 common shares for services, recognized $113,292 of related expense, and issued 1,575,000 warrants during the quarter. The CEO and CFO received warrants for 1,000,000 and 500,000 shares, respectively, with a $0.30 exercise price; $210,000 of compensation expense was recognized.
- The fair value of the derivative liability declined by $24,250, producing $40,750 of other income from remeasurement.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expected 2013 biotech intellectual-property revenue to exceed 2012 levels, but provided no specific revenue guidance and stated that achievement was uncertain. The company continued testing and development of its clean-energy systems and acknowledged that substantial losses would continue until successful commercialization, for which there could be no assurance.
The financial statements include a going-concern uncertainty. The company reported recurring operating losses, negative operating cash flow, limited liquidity, and a need to promptly raise substantial additional capital. Management warned that failure to obtain funding could force the company to cease operations.
- Technical problems with the company’s systems delayed the commencement of minimum sales requirements under its exclusive European license agreement.
- The company remained dependent on private debt and equity financing, licensing revenue, and related-party funding.
- The 2012 goodwill balance related to the Cornerstone acquisition had previously been fully impaired. Intellectual property remained on the balance sheet at $439,626 net.
- Derivative valuations used option-pricing models and were sensitive to changes in the company’s share price, volatility, interest rates, and other assumptions.
- Management concluded that disclosure controls and procedures were not effective. A material weakness related to monitoring and supervision of accounting operations continued during the quarter.
- The company reported no material changes to previously disclosed risk factors, no legal proceedings, and no defaults upon senior securities.
- Potential dilution was significant: 7,512,666 warrants and 2,750,000 options were excluded from diluted loss-per-share calculations because their effect was anti-dilutive.
Investor Verification Checklist
- Verify the registrant identity and corporate-name history, because the filing names PowerVerde, Inc., while the request metadata identifies 374Water Inc.
- Assess the going-concern disclosure, available cash of $12,732, working-capital deficit, and the company’s ability to obtain additional financing.
- Review the terms, collateral provisions, interest obligations, and maturity of the $400,000 aggregate secured promissory notes, including the $75,000 raised in the quarter.
- Evaluate whether licensing revenue is recurring and whether technical issues will prevent product commercialization or trigger minimum-sales obligations.
- Review related-party balances and transactions, including the $363,370 payable balance and continued use of a facility owned by a former officer and director.
- Consider dilution from outstanding warrants, options, and equity issued for services.
- Investigate the disclosed material weakness in internal controls and whether remediation has occurred after March 31, 2013.
- Confirm the valuation and future recoverability of the remaining intellectual-property asset and the assumptions underlying derivative-liability measurements.